Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (HK:8049)

:8049

8049

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H

RESEARCH TOOLSreports

Want to see HK:8049 full AI Analyst Report?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) Price & Analysis

1 Followers

8049 Stock Chart & Stats

HK$2.16

-HK$0.03(-2.08%)

At close: Jan 09 4:00 PM EST

HK$2.16

-HK$0.03(-2.08%)

Day’s Range― - ―

52-Week RangeHK$1.82 - HK$2.60

Previous CloseN/A

Volume24.00K

Average Volume (3M)47.79K

Market Cap

HK$1.40B

Enterprise ValueHK$1.09B

Total Cash (Recent Filing)HK$748.30M

Total Debt (Recent Filing)HK$72.40M

Price to Earnings (P/E)6.1

Beta0.44

Next Earnings

Aug 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.32

Shares Outstanding172,500,000

10 Day Avg. Volume34,000

30 Day Avg. Volume47,793

Financial Highlights & Ratios

PEG Ratio0.91

Price to Book (P/B)0.65

Price to Sales (P/S)1.22

P/FCF Ratio3.65

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetA consistently conservative balance sheet with low leverage and growing equity strengthens financial resilience. This durable capital base lowers insolvency risk, supports funding for R&D or expansions without heavy external financing, and provides flexibility through business cycles.

Sustained High ProfitabilityHigh and stable gross and net margins across multiple years indicate structural pricing power or cost efficiency in specialty/generic operations. Persistent margins support reinvestment, cover fixed costs, and make earnings more resilient to revenue fluctuations over the medium term.

Strong Cash GenerationFree cash flow that tracks net income and recently improved to a very strong level signals sustainable internal funding for capex, working capital, and shareholder returns. Reliable cash conversion enhances strategic optionality and reduces dependence on external capital.

Bears Say

Cooling Revenue MomentumTop-line momentum has cooled from prior expansion, with recent flat-to-declining revenue. Sustained revenue weakness would limit absolute earnings growth and may indicate competitive pressure or market saturation in core products, constraining long-term scaling and investment returns.

Cash Flow VolatilityMaterial year-to-year swings in free cash flow complicate forecasting and durable capital allocation. Volatility can force conservative spending or raise the cost of financing in down years, reducing the firm's ability to consistently fund growth initiatives or maintain distributions.

Rising Debt In 2023–2024The increase in debt in 2023–2024, while currently manageable, raises medium-term refinancing and interest-rate sensitivity. If revenue stalls, higher leverage reduces buffer for shocks and may constrain strategic moves or require diverting cash to deleveraging rather than growth investments.

8049 FAQ

What was Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price range in the past 12 months?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H lowest stock price was HK$1.82 and its highest was HK$2.60 in the past 12 months.

What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap is HK$1.40B.

When is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date is Aug 19, 2026 which is in 68 days.

How were Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s earnings last quarter?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H released its earnings results on Mar 31, 2026. The company reported HK$0.187 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.187.

Is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H overvalued?

According to Wall Street analysts Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H pay dividends?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H pays a Notavailable dividend of HK$0.288 which represents an annual dividend yield of N/A. See more information on Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H dividends here

What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H have?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H has 172,500,000 shares outstanding.

What happened to Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price movement after its last earnings report?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H reported an EPS of HK$0.187 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.304%.

Which hedge fund is a major shareholder of Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:8049

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H

Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio includes a wide range of dosage forms such as tablets, capsules, and pills, as well as specialized items like Chinese medicine pretreatment and extraction products. They also provide various injectable solutions, including powders for injection, lyophilized powders for injection, and small volume liquid injections, along with active pharmaceutical ingredients (APIs) and granules. These products are primarily sold under the "Changlong" and "Qing Tong" brand names. Established in 1989, and headquartered in Kowloon, Hong Kong, the company was previously known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited.